| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | translation activator activity | 1.45e-07 | 15 | 66 | 4 | GO:0008494 | |
| GeneOntologyBiologicalProcess | female meiosis II | 1.43e-09 | 6 | 66 | 4 | GO:0007147 | |
| GeneOntologyBiologicalProcess | meiosis II | 1.43e-09 | 6 | 66 | 4 | GO:0007135 | |
| GeneOntologyBiologicalProcess | meiosis II cell cycle process | 1.43e-09 | 6 | 66 | 4 | GO:0061983 | |
| GeneOntologyBiologicalProcess | positive regulation of meiotic nuclear division | 1.36e-06 | 26 | 66 | 4 | GO:0045836 | |
| GeneOntologyBiologicalProcess | positive regulation of translational initiation | 2.14e-06 | 29 | 66 | 4 | GO:0045948 | |
| GeneOntologyBiologicalProcess | 3'-UTR-mediated mRNA stabilization | 2.82e-06 | 31 | 66 | 4 | GO:0070935 | |
| GeneOntologyBiologicalProcess | positive regulation of meiotic cell cycle | 5.83e-06 | 37 | 66 | 4 | GO:0051446 | |
| GeneOntologyBiologicalProcess | oogenesis | 1.06e-05 | 156 | 66 | 6 | GO:0048477 | |
| GeneOntologyBiologicalProcess | regulation of meiotic nuclear division | 1.29e-05 | 45 | 66 | 4 | GO:0040020 | |
| GeneOntologyBiologicalProcess | oocyte maturation | 1.54e-05 | 47 | 66 | 4 | GO:0001556 | |
| GeneOntologyBiologicalProcess | oocyte development | 1.63e-05 | 99 | 66 | 5 | GO:0048599 | |
| GeneOntologyBiologicalProcess | oocyte differentiation | 1.98e-05 | 103 | 66 | 5 | GO:0009994 | |
| GeneOntologyBiologicalProcess | female meiotic nuclear division | 2.31e-05 | 52 | 66 | 4 | GO:0007143 | |
| GeneOntologyBiologicalProcess | female gamete generation | 7.90e-05 | 223 | 66 | 6 | GO:0007292 | |
| GeneOntologyBiologicalProcess | positive regulation of nuclear division | 9.80e-05 | 75 | 66 | 4 | GO:0051785 | |
| GeneOntologyBiologicalProcess | mRNA stabilization | 1.09e-04 | 77 | 66 | 4 | GO:0048255 | |
| GeneOntologyBiologicalProcess | meiotic nuclear division | 1.18e-04 | 240 | 66 | 6 | GO:0140013 | |
| GeneOntologyBiologicalProcess | regulation of meiotic cell cycle | 1.39e-04 | 82 | 66 | 4 | GO:0051445 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA catabolic process | 1.74e-04 | 87 | 66 | 4 | GO:1902373 | |
| GeneOntologyBiologicalProcess | RNA stabilization | 1.82e-04 | 88 | 66 | 4 | GO:0043489 | |
| GeneOntologyBiologicalProcess | regulation of translational initiation | 2.07e-04 | 91 | 66 | 4 | GO:0006446 | |
| GeneOntologyBiologicalProcess | meiotic cell cycle process | 2.15e-04 | 268 | 66 | 6 | GO:1903046 | |
| GeneOntologyBiologicalProcess | regulation of T cell differentiation in thymus | 2.25e-04 | 37 | 66 | 3 | GO:0033081 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA catabolic process | 3.09e-04 | 101 | 66 | 4 | GO:1902369 | |
| GeneOntologyBiologicalProcess | T cell differentiation in thymus | 4.90e-04 | 114 | 66 | 4 | GO:0033077 | |
| GeneOntologyBiologicalProcess | negative regulation of mRNA metabolic process | 5.06e-04 | 115 | 66 | 4 | GO:1903312 | |
| GeneOntologyBiologicalProcess | positive regulation of reproductive process | 5.58e-04 | 118 | 66 | 4 | GO:2000243 | |
| GeneOntologyBiologicalProcess | regulation of T cell activation | 6.40e-04 | 458 | 66 | 7 | GO:0050863 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell differentiation in thymus | 7.69e-04 | 13 | 66 | 2 | GO:0033089 | |
| GeneOntologyBiologicalProcess | regulation of T cell differentiation | 7.84e-04 | 226 | 66 | 5 | GO:0045580 | |
| GeneOntologyBiologicalProcess | translational initiation | 8.50e-04 | 132 | 66 | 4 | GO:0006413 | |
| GeneOntologyBiologicalProcess | germ cell development | 8.63e-04 | 482 | 66 | 7 | GO:0007281 | |
| GeneOntologyBiologicalProcess | meiotic cell cycle | 8.82e-04 | 350 | 66 | 6 | GO:0051321 | |
| Domain | NUT | 1.15e-04 | 5 | 64 | 2 | IPR024310 | |
| Domain | NUT_N | 1.15e-04 | 5 | 64 | 2 | IPR024309 | |
| Domain | NUT | 1.15e-04 | 5 | 64 | 2 | PF12881 | |
| Domain | Znf_FYVE_PHD | 1.48e-04 | 147 | 64 | 5 | IPR011011 | |
| Domain | RasGEFN | 2.11e-03 | 20 | 64 | 2 | SM00229 | |
| Domain | Synaptotagmin | 2.11e-03 | 20 | 64 | 2 | IPR001565 | |
| Domain | RasGEF_N | 2.33e-03 | 21 | 64 | 2 | PF00618 | |
| Domain | EPHD | 2.55e-03 | 22 | 64 | 2 | PS51805 | |
| Domain | Ras-like_Gua-exchang_fac_N | 2.55e-03 | 22 | 64 | 2 | IPR000651 | |
| Domain | RASGEF_NTER | 2.55e-03 | 22 | 64 | 2 | PS50212 | |
| Domain | RASGEF | 3.56e-03 | 26 | 64 | 2 | PS00720 | |
| Domain | - | 4.32e-03 | 449 | 64 | 6 | 3.30.40.10 | |
| Domain | ZF_PHD_1 | 4.37e-03 | 96 | 64 | 3 | PS01359 | |
| Domain | RASGEF_CAT | 4.42e-03 | 29 | 64 | 2 | PS50009 | |
| Domain | RasGEF | 4.73e-03 | 30 | 64 | 2 | PF00617 | |
| Domain | - | 4.73e-03 | 30 | 64 | 2 | 1.10.840.10 | |
| Domain | Ras_GEF_dom | 4.73e-03 | 30 | 64 | 2 | IPR023578 | |
| Domain | RASGEF_cat_dom | 4.73e-03 | 30 | 64 | 2 | IPR001895 | |
| Domain | RasGEF | 4.73e-03 | 30 | 64 | 2 | SM00147 | |
| Domain | Znf_RING/FYVE/PHD | 4.80e-03 | 459 | 64 | 6 | IPR013083 | |
| Domain | Ig_V-set | 4.83e-03 | 199 | 64 | 4 | IPR013106 | |
| Domain | RRM_1 | 5.64e-03 | 208 | 64 | 4 | PF00076 | |
| Domain | RRM | 6.54e-03 | 217 | 64 | 4 | SM00360 | |
| Domain | RRM_dom | 7.64e-03 | 227 | 64 | 4 | IPR000504 | |
| Domain | RRM | 7.99e-03 | 230 | 64 | 4 | PS50102 | |
| Pathway | WP_OVARIAN_INFERTILITY | 3.33e-06 | 35 | 42 | 4 | MM15948 | |
| Pathway | REACTOME_INTEGRIN_SIGNALING | 6.84e-05 | 27 | 42 | 3 | M760 | |
| Pathway | REACTOME_INTEGRIN_SIGNALING | 7.65e-05 | 28 | 42 | 3 | MM14958 | |
| Pathway | REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION | 1.93e-04 | 38 | 42 | 3 | MM15456 | |
| Pathway | REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION | 2.09e-04 | 39 | 42 | 3 | M10735 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 2.48e-04 | 301 | 42 | 6 | MM15983 | |
| Pubmed | Analysis of the DAZ gene family in cryptorchidism and idiopathic male infertility. | 1.26e-11 | 4 | 67 | 4 | 15066457 | |
| Pubmed | 1.26e-11 | 4 | 67 | 4 | 7670487 | ||
| Pubmed | Impact of partial DAZ1/2 deletion and partial DAZ3/4 deletion on male infertility. | 1.26e-11 | 4 | 67 | 4 | 26232607 | |
| Pubmed | 1.26e-11 | 4 | 67 | 4 | 11694340 | ||
| Pubmed | 1.26e-11 | 4 | 67 | 4 | 9321470 | ||
| Pubmed | 1.26e-11 | 4 | 67 | 4 | 19223287 | ||
| Pubmed | Male infertility caused by a de novo partial deletion of the DAZ cluster on the Y chromosome. | 1.26e-11 | 4 | 67 | 4 | 11095434 | |
| Pubmed | [Microdeletion of chromosome Y in male infertility: role of the DAZ gene]. | 1.26e-11 | 4 | 67 | 4 | 11688365 | |
| Pubmed | 1.26e-11 | 4 | 67 | 4 | 12752250 | ||
| Pubmed | A novel approach for the analysis of DAZ gene copy number in severely idiopathic infertile men. | 1.26e-11 | 4 | 67 | 4 | 11883873 | |
| Pubmed | Four DAZ genes in two clusters found in the AZFc region of the human Y chromosome. | 1.26e-11 | 4 | 67 | 4 | 10936047 | |
| Pubmed | [Study on DAZ gene copy deletion in severe oligozoospermia sperm donor for ICSI]. | 1.26e-11 | 4 | 67 | 4 | 16963411 | |
| Pubmed | Partial DAZ deletions in a family with five infertile brothers. | 1.26e-11 | 4 | 67 | 4 | 12801575 | |
| Pubmed | 4.50e-11 | 14 | 67 | 5 | 30102701 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 23298641 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 23579190 | ||
| Pubmed | DAZL is essential for stress granule formation implicated in germ cell survival upon heat stress. | 6.28e-11 | 5 | 67 | 4 | 22223682 | |
| Pubmed | Kinked β-strands mediate high-affinity recognition of mRNA targets by the germ-cell regulator DAZL. | 6.28e-11 | 5 | 67 | 4 | 22021443 | |
| Pubmed | The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis. | 6.28e-11 | 5 | 67 | 4 | 9288969 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 20008336 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 23456578 | ||
| Pubmed | Isolation of a mouse homolog of the human DAZ (Deleted in Azoospermia) gene. | 6.28e-11 | 5 | 67 | 4 | 8679003 | |
| Pubmed | A human DAZ transgene confers partial rescue of the mouse Dazl null phenotype. | 6.28e-11 | 5 | 67 | 4 | 10393944 | |
| Pubmed | The human autosomal gene DAZLA: testis specificity and a candidate for male infertility. | 6.28e-11 | 5 | 67 | 4 | 8968756 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 8968755 | ||
| Pubmed | DAZL Regulates Germ Cell Survival through a Network of PolyA-Proximal mRNA Interactions. | 6.28e-11 | 5 | 67 | 4 | 30380414 | |
| Pubmed | Regulated Formation of an Amyloid-like Translational Repressor Governs Gametogenesis. | 6.28e-11 | 5 | 67 | 4 | 26411291 | |
| Pubmed | In vivo and in vitro analysis of homodimerisation activity of the mouse Dazl1 protein. | 6.28e-11 | 5 | 67 | 4 | 10903443 | |
| Pubmed | Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. | 6.28e-11 | 5 | 67 | 4 | 23223451 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 34985827 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 11804965 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 9143498 | ||
| Pubmed | Expression profiling of the developing testis in wild-type and Dazl knockout mice. | 6.28e-11 | 5 | 67 | 4 | 14648873 | |
| Pubmed | Bisphenol A exposure modifies DNA methylation of imprint genes in mouse fetal germ cells. | 6.28e-11 | 5 | 67 | 4 | 22699882 | |
| Pubmed | A murine homologue of the human DAZ gene is autosomal and expressed only in male and female gonads. | 6.28e-11 | 5 | 67 | 4 | 8845845 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 8896558 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 11058556 | ||
| Pubmed | AZFc partial deletions in Chilean men with severe spermatogenic failure. | 6.28e-11 | 5 | 67 | 4 | 17416365 | |
| Pubmed | Dazl promotes germ cell differentiation from embryonic stem cells. | 6.28e-11 | 5 | 67 | 4 | 19783541 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 22293198 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 17761180 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 19468308 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 9700189 | ||
| Pubmed | Partial rescue of the Dazl knockout mouse by the human DAZL gene. | 6.28e-11 | 5 | 67 | 4 | 12200456 | |
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 11514340 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 21270429 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 11089564 | ||
| Pubmed | 6.28e-11 | 5 | 67 | 4 | 8661148 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 32170089 | ||
| Pubmed | Expression profiles of the DAZ gene family in human testis with and without spermatogenic failure. | 1.88e-10 | 6 | 67 | 4 | 15066460 | |
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 16278232 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 20157580 | ||
| Pubmed | DAZL binds to the transcripts of several Tssk genes in germ cells. | 1.88e-10 | 6 | 67 | 4 | 18452650 | |
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 17219433 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 28496037 | ||
| Pubmed | DAZL regulates Tet1 translation in murine embryonic stem cells. | 1.88e-10 | 6 | 67 | 4 | 26077710 | |
| Pubmed | The DAZL family proteins are PABP-binding proteins that regulate translation in germ cells. | 1.88e-10 | 6 | 67 | 4 | 16001084 | |
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 32962040 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 17526644 | ||
| Pubmed | Genetic mapping of a male germ cell-expressed gene Tpx-2 to mouse chromosome 17. | 1.88e-10 | 6 | 67 | 4 | 1869307 | |
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 11390979 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 24086306 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 27632217 | ||
| Pubmed | 1.88e-10 | 6 | 67 | 4 | 1638086 | ||
| Pubmed | Spermatogenesis in testes of Dazl null mice after transplantation of wild-type germ cells. | 1.88e-10 | 6 | 67 | 4 | 14611632 | |
| Pubmed | DAZL binds to 3'UTR of Tex19.1 mRNAs and regulates Tex19.1 expression. | 1.88e-10 | 6 | 67 | 4 | 19247806 | |
| Pubmed | DAZL is a master translational regulator of murine spermatogenesis. | 1.88e-10 | 6 | 67 | 4 | 31355046 | |
| Pubmed | The fate of granulosa cells following premature oocyte loss and the development of ovarian cancers. | 1.88e-10 | 6 | 67 | 4 | 23417416 | |
| Pubmed | 4.38e-10 | 7 | 67 | 4 | 11410654 | ||
| Pubmed | 4.38e-10 | 7 | 67 | 4 | 15081113 | ||
| Pubmed | 4.38e-10 | 7 | 67 | 4 | 22699423 | ||
| Pubmed | 4.38e-10 | 7 | 67 | 4 | 11604102 | ||
| Pubmed | 4.38e-10 | 7 | 67 | 4 | 10857750 | ||
| Pubmed | The Dazh gene is expressed in male and female embryonic gonads before germ cell sex differentiation. | 4.38e-10 | 7 | 67 | 4 | 9588208 | |
| Pubmed | DAZL and CPEB1 regulate mRNA translation synergistically during oocyte maturation. | 4.38e-10 | 7 | 67 | 4 | 26826184 | |
| Pubmed | Dazl can bind to dynein motor complex and may play a role in transport of specific mRNAs. | 4.38e-10 | 7 | 67 | 4 | 16946704 | |
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 10951504 | ||
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 33749946 | ||
| Pubmed | Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. | 8.75e-10 | 8 | 67 | 4 | 23204224 | |
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 29883445 | ||
| Pubmed | Mouse dead end1 acts with Nanos2 and Nanos3 to regulate testicular teratoma incidence. | 8.75e-10 | 8 | 67 | 4 | 32339196 | |
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 10823932 | ||
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 22621333 | ||
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 32686646 | ||
| Pubmed | 8.75e-10 | 8 | 67 | 4 | 11869379 | ||
| Pubmed | A Gene Regulatory Program for Meiotic Prophase in the Fetal Ovary. | 1.57e-09 | 9 | 67 | 4 | 26378784 | |
| Pubmed | Dazl deficiency leads to embryonic arrest of germ cell development in XY C57BL/6 mice. | 1.57e-09 | 9 | 67 | 4 | 16310179 | |
| Pubmed | Embryoid bodies from mouse stem cells express oxytocin receptor, Oct-4 and DAZL. | 1.57e-09 | 9 | 67 | 4 | 19695304 | |
| Pubmed | 1.57e-09 | 9 | 67 | 4 | 28235998 | ||
| Pubmed | 1.57e-09 | 9 | 67 | 4 | 20159962 | ||
| Pubmed | 2.62e-09 | 10 | 67 | 4 | 10601091 | ||
| Pubmed | 2.62e-09 | 10 | 67 | 4 | 31234534 | ||
| Pubmed | Tesmin transcription is regulated differently during male and female meiosis. | 2.62e-09 | 10 | 67 | 4 | 14648882 | |
| Pubmed | MAX controls meiotic entry in sexually undifferentiated germ cells. | 2.62e-09 | 10 | 67 | 4 | 38433229 | |
| Pubmed | 2.62e-09 | 10 | 67 | 4 | 9922113 | ||
| Pubmed | 2.62e-09 | 10 | 67 | 4 | 23810942 | ||
| Pubmed | 2.62e-09 | 10 | 67 | 4 | 12837688 | ||
| Pubmed | NANOS2 suppresses the cell cycle by repressing mTORC1 activators in embryonic male germ cells. | 4.11e-09 | 11 | 67 | 4 | 34401671 | |
| Pubmed | Retinoic acid activates two pathways required for meiosis in mice. | 6.15e-09 | 12 | 67 | 4 | 25102060 | |
| Pubmed | 6.15e-09 | 12 | 67 | 4 | 32054698 | ||
| Cytoband | Yq11.223 | 1.10e-05 | 93 | 67 | 4 | Yq11.223 | |
| Coexpression | TESAR_JAK_TARGETS_MOUSE_ES_D3_DN | 1.68e-08 | 12 | 65 | 4 | MM742 | |
| Coexpression | SASAI_TARGETS_OF_CXCR6_AND_PTCH1_DN | 1.68e-08 | 12 | 65 | 4 | MM781 | |
| Coexpression | WAGSCHAL_EHMT2_TARGETS_UP | 2.94e-07 | 23 | 65 | 4 | MM1293 | |
| Coexpression | MATZUK_SPERMATOGONIA | 1.03e-06 | 31 | 65 | 4 | MM765 | |
| Coexpression | CHEN_ETV5_TARGETS_TESTIS | 1.33e-06 | 33 | 65 | 4 | MM701 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C1_INTERM_NEUROENDOCRINE_CELL | 4.53e-06 | 268 | 65 | 7 | M45696 | |
| Coexpression | MADAN_DPPA4_TARGETS | 6.28e-05 | 86 | 65 | 4 | MM1312 | |
| Coexpression | JACKSON_DNMT1_TARGETS_UP | 8.52e-05 | 93 | 65 | 4 | MM1185 | |
| Coexpression | GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_2H_ACT_CD4_TCELL_UP | 1.31e-04 | 197 | 65 | 5 | M4211 | |
| Coexpression | GSE411_UNSTIM_VS_400MIN_IL6_STIM_SOCS3_KO_MACROPHAGE_DN | 1.37e-04 | 199 | 65 | 5 | M6003 | |
| Coexpression | GSE27786_NKTCELL_VS_ERYTHROBLAST_DN | 1.40e-04 | 200 | 65 | 5 | M4867 | |
| Coexpression | GSE8868_SPLEEN_VS_INTESTINE_CD11B_POS_CD11C_NEG_DC_UP | 1.40e-04 | 200 | 65 | 5 | M5772 | |
| Coexpression | MCCABE_BOUND_BY_HOXC6 | 1.44e-04 | 461 | 65 | 7 | M6376 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_1000_k-means-cluster#1 | 1.56e-05 | 259 | 66 | 7 | Facebase_RNAseq_e8.5_Floor Plate_1000_K1 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_500_k-means-cluster#3 | 3.32e-05 | 118 | 66 | 5 | Facebase_RNAseq_e8.5_Floor Plate_500_K3 | |
| CoexpressionAtlas | CD positive, CD4 Control, 4+ 8- B220-, Spleen, avg-4 | 4.83e-05 | 210 | 66 | 6 | GSM403995_500 | |
| CoexpressionAtlas | CD positive, CD4 Control, 4+8-B220-, Spleen, avg-2 | 6.91e-05 | 224 | 66 | 6 | GSM403994_500 | |
| ToppCell | human_hepatoblastoma-NK.T_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 1.40e-08 | 188 | 67 | 7 | 71b7599e7e1d63cc0c8518c0501533755951d58f | |
| ToppCell | Fetal_29-31_weeks-Immune-T_lymphocyte-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.62e-08 | 192 | 67 | 7 | 92f141d5ac462f652f405efa73ac6ef751f40ea3 | |
| ToppCell | Fetal_29-31_weeks-Immune-T_lymphocyte|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.62e-08 | 192 | 67 | 7 | 69a2b04f03a1b82d067018379f7b8a116e954040 | |
| ToppCell | human_hepatoblastoma-NK.T_cells|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells) | 1.74e-08 | 194 | 67 | 7 | 997b02a22d7c89a8fd5615bb79a2a8a34fc3fee6 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells-T-cells|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.27e-07 | 171 | 67 | 6 | 539ea88acc6f948efdeae8b69e5c5ffaee29f1d9 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.27e-07 | 171 | 67 | 6 | 55c7bf7211587fa08df13c0a4ff5b78a85d5439e | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.35e-07 | 172 | 67 | 6 | 0fc692be845d4225ff8b63bf9195724fc8510c2c | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-07 | 176 | 67 | 6 | 9d4a4dfeebb5a8a0f3ab18c37c8ddc2cd2158575 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-T_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-07 | 176 | 67 | 6 | bb41e9478373726eb460af764de0277b2d09928e | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-T_cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-07 | 176 | 67 | 6 | ea27e18407b8a13e8212830da859efeb8f158690 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-T_cells-T-cells|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-07 | 176 | 67 | 6 | bfbab3c5b738b3b0b1540f2059d0245fbd8c0031 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.78e-07 | 177 | 67 | 6 | f1efd9c3074d5635700fe7fbebf3dd0b1e0a84f1 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.98e-07 | 179 | 67 | 6 | ecea75c568911ff56939c9f67ab901497bd4356c | |
| ToppCell | LPS_only-Lymphocytic_NKT-T_cells-T-cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.07e-07 | 180 | 67 | 6 | dcef253f2e97e4436b1b04e8a06a53ff6e64522c | |
| ToppCell | COVID-19-T_cells-Tregs|COVID-19 / group, cell type (main and fine annotations) | 3.18e-07 | 181 | 67 | 6 | 534659cf754326c6a73c0daa30e9d610612a0292 | |
| ToppCell | LPS_only-Lymphocytic_NKT-T_cells|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.18e-07 | 181 | 67 | 6 | a4347ae554e6dcf03c7001a2b69332b377c7c034 | |
| ToppCell | Control-T_cells|Control / group, cell type (main and fine annotations) | 3.85e-07 | 187 | 67 | 6 | f4e8e0eba58da89b56587667555a5d4754e108c7 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 4.09e-07 | 189 | 67 | 6 | 3b48b0d220cc24d5170713d61fa91f5bb6c21841 | |
| ToppCell | Fetal_29-31_weeks-Immune-T_lymphocyte-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.22e-07 | 190 | 67 | 6 | 2a8de1cf27a9ebc3825cf9e7a489ecd064dfc7f9 | |
| ToppCell | Control-T_cells-CD4+_T_cells|Control / group, cell type (main and fine annotations) | 4.22e-07 | 190 | 67 | 6 | 0733be5e54fe15d6d6ea51c154a95258e83f1b92 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_T/NK-T_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.22e-07 | 190 | 67 | 6 | 07ea0578ca0561077557203ae660530f53fc4067 | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-NK|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 4.22e-07 | 190 | 67 | 6 | 86b0d142b7d1a3b35580edd104f947106be2c9c6 | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_T/NK-T_Cell-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.22e-07 | 190 | 67 | 6 | 5b4b3eed7aa798bb7e3c5e968c8dc4144e377a5f | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_T/NK|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 4.35e-07 | 191 | 67 | 6 | 96a7179a845d3daa046ed71fa45c51255f130a7f | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.77e-07 | 194 | 67 | 6 | 633fe72cc8a489abde12428e326478409ca03263 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.77e-07 | 194 | 67 | 6 | 87a86df0b542f287b0b20f4a4b1a37002271671d | |
| ToppCell | Immune-T_lymphocyte|World / Lineage, Cell type, age group and donor | 4.77e-07 | 194 | 67 | 6 | f47fa18c87b35a3960557f8169ff7830dd6ecb80 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.92e-07 | 195 | 67 | 6 | cab90c67a7b3119c0d0d2d5e84511c41dcb8765f | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.06e-07 | 196 | 67 | 6 | c9fb81a0578db6d278b8582d7b3add6c407e6dcf | |
| ToppCell | control-CD8+_T_naive|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 5.54e-07 | 199 | 67 | 6 | 6a61ce7404c65e506091fee99a2001f5a9b39f31 | |
| ToppCell | Bronchial-NucSeq-Immune_Lymphocytic-T|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.70e-07 | 200 | 67 | 6 | c6c2b39359c65c9444987d02d1c899dff2ad1366 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-T_cells-Erythroid|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.44e-06 | 128 | 67 | 5 | c2045f052cc713e52312eb015825711576fcb6c5 | |
| ToppCell | Control-T_cells-Tregs|Control / group, cell type (main and fine annotations) | 5.64e-06 | 169 | 67 | 5 | e1e0983f31ec81b3fad5f9c6140d17f03f81a5dc | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Hematopoietic-T_cells-NK_T_cell|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.87e-06 | 176 | 67 | 5 | 1ea45cf7b7e12206c3eca1594173368643c50e59 | |
| ToppCell | Control-Lymphocytic_NKT-T_cells-T-cells|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.25e-06 | 178 | 67 | 5 | 910f8bea19d335455aba24e6a07b4834b709db5d | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.45e-06 | 179 | 67 | 5 | 5ccf0824611ded5c673d94dff3048aedac12f1a8 | |
| ToppCell | Control-Lymphocytic_NKT-T_cells|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.45e-06 | 179 | 67 | 5 | d892d9496f1c33e23312092591eb2e968e736f7d | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-T_&_ILC-ILC3|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 7.87e-06 | 181 | 67 | 5 | bf2bd5ecec1e23a44f719d7efeb1f45d6c1c6b32 | |
| ToppCell | LV-17._Lymphocyte|LV / Chamber and Cluster_Paper | 7.87e-06 | 181 | 67 | 5 | 81fafa69c8c240250a667a5f3b321e8be1b9a288 | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-T_&_ILC-ILCP|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 8.30e-06 | 183 | 67 | 5 | 797eb968c57e48db33ff8e2236ee22e9425c4676 | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-T_&_ILC|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 8.52e-06 | 184 | 67 | 5 | 51ae0963b4fb034c3f605ee4e5da513cba7aca35 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c01-LEF1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.52e-06 | 184 | 67 | 5 | 5350b58aa9979631228835d11eb45ddf81d08bff | |
| ToppCell | droplet-Lung-21m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 8.75e-06 | 185 | 67 | 5 | 1b990e3089772be2b38c6d7ea0d1bf22461ae3ea | |
| ToppCell | Control-T_cells-CD8+_T_cells|Control / group, cell type (main and fine annotations) | 8.75e-06 | 185 | 67 | 5 | 02ab64c0166c0646d1d4c6ed110ef0b75a1096d0 | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_T-T_NK-CD4_T_cell|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 8.75e-06 | 185 | 67 | 5 | 32f43ddc8a899827924834546db33928e353271b | |
| ToppCell | 15-Distal-Immune-Hematopoietic,_T_Cells|Distal / Age, Tissue, Lineage and Cell class | 8.75e-06 | 185 | 67 | 5 | 481e3d3b63f2e5b4783088523c3cf70a461aed27 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 8.98e-06 | 186 | 67 | 5 | 9d576dce2c5deefef1adda16c6da7055c8d57f8f | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 8.98e-06 | 186 | 67 | 5 | bd3bd022b575d9b0ef90d50a5cb874085a827b77 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 8.98e-06 | 186 | 67 | 5 | 924cc357b4c4ce8e9b05773bdab544f0b65474cc | |
| ToppCell | -Unknown-Endothelial-Myofibroblast| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.45e-06 | 188 | 67 | 5 | 6468fa95ad0395395301115286f2d8c0df5d3882 | |
| ToppCell | -Unknown-Endothelial| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.45e-06 | 188 | 67 | 5 | 7a81ac5c79c3eb26639b52d2b9fd5e7ef9798fd6 | |
| ToppCell | -Unknown| / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.45e-06 | 188 | 67 | 5 | 9cb718bfe1358c6fd842f096e228eb0abb9aefc6 | |
| ToppCell | LPS_only-Lymphocytic_NKT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.45e-06 | 188 | 67 | 5 | bbe65b1c11c88ab62d8485cfc3a913ff9da89aad | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-NK-Intermediate_NK|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 9.45e-06 | 188 | 67 | 5 | a8170e4ce6406af9f5ad5317e6e26efa7bc66411 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.70e-06 | 189 | 67 | 5 | b87d586a9570fa54f3e0c6bd4731c5badcaedae6 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.70e-06 | 189 | 67 | 5 | d05e043d0874b8563b9f5514f6c884b35c603e3a | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.70e-06 | 189 | 67 | 5 | 823d6debd09e440ddf36c54af24a5f20e222a21e | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.70e-06 | 189 | 67 | 5 | 47c2b419b081d5bf75da5e3d9a0e05a70362dfe7 | |
| ToppCell | CF-Lymphoid-B_cell|CF / Disease state, Lineage and Cell class | 9.95e-06 | 190 | 67 | 5 | 374d8fd63c733178acab07682ed1519693efab45 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.95e-06 | 190 | 67 | 5 | ba61f04fd38efae01f721ba616252d1372ff1002 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-T_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.95e-06 | 190 | 67 | 5 | 5a37568000dfc33fcbb59b578c1963fb7cf872ec | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_T-T_NK-CD4_T_cell|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 9.95e-06 | 190 | 67 | 5 | 8fdf35c2ad1d325c00c00e4fcf2506341ff14537 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Hematopoietic-T_cells-SELL+_CD8_T|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 9.95e-06 | 190 | 67 | 5 | d83fdc352ebb0c2f2a7c2138bf6e3b7a8ce83a6a | |
| ToppCell | Fetal_29-31_weeks-Immune-T_lymphocyte-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.02e-05 | 191 | 67 | 5 | 133864ec1e89f97a82c3bb01d2a3c658397fefaf | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.02e-05 | 191 | 67 | 5 | d9506b88d806aadd4c2b9bf86fe994c47799e7f6 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.02e-05 | 191 | 67 | 5 | b42c54308abe1241cc38ddce96b9d38d07983891 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.02e-05 | 191 | 67 | 5 | d9a6f61fcda4f5352488f7f55cb9b57aeacc717f | |
| ToppCell | COVID-19-lung-CD4+_Treg|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.02e-05 | 191 | 67 | 5 | 5a4ad5ae5c2dbfb225158cb598ef649c26a48350 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.02e-05 | 191 | 67 | 5 | 1cb02007adb344f17ef73d58890f91298c7cf5a1 | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_DC-DC-pDC|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.02e-05 | 191 | 67 | 5 | faf4de97003a938a243b0101456913c2b0e1804f | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.02e-05 | 191 | 67 | 5 | c7be771543089fc94e5c62fd22f745189642aec3 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.02e-05 | 191 | 67 | 5 | 696921a4f160b6b55698652488ed781e855e5e51 | |
| ToppCell | COVID-19-T_cells-CD4+_T_cells|COVID-19 / group, cell type (main and fine annotations) | 1.02e-05 | 191 | 67 | 5 | 0646cca78e24aeb6baa9934d3c439b797c567997 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Lymphocytic_T/NK-T_Cell-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 1.02e-05 | 191 | 67 | 5 | 9aabbc65430e2233b8f2d3fff9face7807b88b48 | |
| ToppCell | COVID-19-T_cells|COVID-19 / group, cell type (main and fine annotations) | 1.02e-05 | 191 | 67 | 5 | 7f64add931b64b8d35836fa6bee9ebab593844d3 | |
| ToppCell | COVID-19-lung-CD4+_Treg|lung / Disease (COVID-19 only), tissue and cell type | 1.02e-05 | 191 | 67 | 5 | 73ea3078c1f55cd47e4d99e77b3ce4ff17549d49 | |
| ToppCell | NS-critical-d_07-13-Lymphoid-Treg|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.05e-05 | 192 | 67 | 5 | cd34defac6565d34db507918e791b09c79f7d1f8 | |
| ToppCell | NS-moderate-d_16-33-Lymphoid-Treg|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.05e-05 | 192 | 67 | 5 | 48d557071bad80edd3ec6e5ad8dcd97037da9553 | |
| ToppCell | moderate-Lymphoid-Treg|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.05e-05 | 192 | 67 | 5 | e370ff5aaff7b7042ba9aaf93de43aa563b8b9f9 | |
| ToppCell | 18-Distal-Immune-Hematopoietic,_T_Cells|Distal / Age, Tissue, Lineage and Cell class | 1.05e-05 | 192 | 67 | 5 | 7538c7f63108f357478ea4c5bf27c1f9825b87c7 | |
| ToppCell | wk_15-18-Hematologic_Lymphocytic-T_&_ILC-CD8_T|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.05e-05 | 192 | 67 | 5 | 375817f1b813d7b2be10738c05611e1d1ba23055 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.07e-05 | 193 | 67 | 5 | 95f5611dd9583f339b7c9f52bb478af204fb89ad | |
| ToppCell | COVID-19-lung-CD4+_T_cells_metabolically_active|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.07e-05 | 193 | 67 | 5 | 326fd2ce2c4b51e5a38f2a7a09f22f8f0e92735a | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.07e-05 | 193 | 67 | 5 | 12f1333f11e6c262954ad7912d8fd2962ab06d25 | |
| ToppCell | COVID-19-kidney-T-cells-1|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.07e-05 | 193 | 67 | 5 | 5b84fa640cf30dea55fde53b810f850ff946d253 | |
| ToppCell | CF-Lymphoid|CF / Disease state, Lineage and Cell class | 1.07e-05 | 193 | 67 | 5 | 11de07d13a7da223990b56fa89ba7fc1c3dd0122 | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.07e-05 | 193 | 67 | 5 | b9769b45125d2244afe53f9f71c92c04ddccf980 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Hematopoietic-T_cells-Activated_T|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.10e-05 | 194 | 67 | 5 | 6385cf2a1529d2e225e407c33da959fccaaca3a4 | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.10e-05 | 194 | 67 | 5 | 3d6f2d190dd50804afea299957cc44c2bb756134 | |
| ToppCell | BAL-Control-Lymphocyte-T/NK-CD4+_T|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.10e-05 | 194 | 67 | 5 | a7f11ac46965b3fc21c9d04870ce0bd2b3868cec | |
| ToppCell | severe_COVID-19-CD4+_T_naive|severe_COVID-19 / disease group, cell group and cell class (v2) | 1.10e-05 | 194 | 67 | 5 | 4b86f3cc173ea779399d5b3598b45b25f60a4395 | |
| ToppCell | critical-Lymphoid-Treg|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 1.10e-05 | 194 | 67 | 5 | deaae292972371b6afae58a023fe2fc05b351bda | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_T|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.13e-05 | 195 | 67 | 5 | 4b9663509cc5e3f409f6d0d37640cb301a827d98 | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-lymphocytic-T_lymphocytic-naive_thymus-derived_CD4-positive,_alpha-beta_T_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.13e-05 | 195 | 67 | 5 | 4e114f6399863406bd87220dea7fb7dfd08824bd | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_T-T_NK|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.13e-05 | 195 | 67 | 5 | 146e482f660c0f234a3d15495ad9e7ed7b88fdc8 | |
| ToppCell | 15-Airway-Immune-Hematopoietic,_T_Cells|Airway / Age, Tissue, Lineage and Cell class | 1.13e-05 | 195 | 67 | 5 | ec392fc8bd2c0f1e3a79f2e401608fd6ba8d339c | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 1.13e-05 | 195 | 67 | 5 | 7f6ff1180c0be199c63dd049700d62dbc792b347 | |
| ToppCell | 10x3'2.3-week_14-16-Lymphocytic_T|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.13e-05 | 195 | 67 | 5 | efc71886b8521539dcba9d5c1a8304eec2dc6c42 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_T-T_NK|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.16e-05 | 196 | 67 | 5 | cd23c6a29ead3f3ec23c871e6e30bb8812bf1973 | |
| ToppCell | 10x5'v1-week_14-16-Lymphocytic_T|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.16e-05 | 196 | 67 | 5 | 6fb93466e53a12f8292da29b9e4952d453b913c3 | |
| Drug | boron trichloride | 9.62e-10 | 6 | 66 | 4 | CID000025135 | |
| Drug | d-gluconhydroximo-1,5-lactam | 2.81e-08 | 31 | 66 | 5 | CID000003479 | |
| Drug | Mimosine [500-44-7]; Down 200; 20.2uM; PC3; HT_HG-U133A | 9.79e-08 | 196 | 66 | 8 | 6703_DN | |
| Drug | Loxapine succinate [27833-64-3]; Down 200; 9uM; PC3; HT_HG-U133A | 1.02e-07 | 197 | 66 | 8 | 6694_DN | |
| Drug | desmethylazelastine | 1.14e-07 | 16 | 66 | 4 | CID000162558 | |
| Drug | dazmegrel | 2.42e-07 | 19 | 66 | 4 | CID000053555 | |
| Drug | YM 026 | 2.42e-07 | 19 | 66 | 4 | CID000004443 | |
| Drug | AZFd | 5.47e-07 | 23 | 66 | 4 | CID000196489 | |
| Drug | dansylaziridine | 5.47e-07 | 23 | 66 | 4 | CID000104008 | |
| Drug | Vistar | 3.54e-06 | 36 | 66 | 4 | CID000040896 | |
| Drug | 3-bromo-7-nitroindazole | 3.54e-06 | 36 | 66 | 4 | CID000001649 | |
| Drug | molybdenum disulfide | 7.30e-06 | 43 | 66 | 4 | CID000014823 | |
| Drug | 2-chlorodideoxyadenosine | 7.30e-06 | 43 | 66 | 4 | CID000072194 | |
| Drug | propham | 8.01e-06 | 44 | 66 | 4 | CID000024685 | |
| Drug | ridogrel | 1.57e-05 | 52 | 66 | 4 | CID005362391 | |
| Drug | Epicatechin-(-) [154-23-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A | 2.23e-05 | 196 | 66 | 6 | 2815_UP | |
| Drug | Hydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; PC3; HT_HG-U133A | 2.23e-05 | 196 | 66 | 6 | 3724_DN | |
| Drug | azafagomine | 2.27e-05 | 57 | 66 | 4 | CID011957435 | |
| Drug | Nadide [53-84-9]; Down 200; 6uM; MCF7; HT_HG-U133A | 2.29e-05 | 197 | 66 | 6 | 7227_DN | |
| Drug | Streptomycin sulfate [3810-74-0]; Down 200; 2.8uM; MCF7; HT_HG-U133A | 2.29e-05 | 197 | 66 | 6 | 7194_DN | |
| Drug | C75; Up 200; 10uM; PC3; HT_HG-U133A | 2.36e-05 | 198 | 66 | 6 | 6428_UP | |
| Drug | Sulfanilamide [63-74-1]; Up 200; 23.2uM; MCF7; HT_HG-U133A | 2.43e-05 | 199 | 66 | 6 | 3449_UP | |
| Drug | Catechin-(+,-) hydrate [7295-85-4]; Up 200; 13.8uM; PC3; HT_HG-U133A | 2.43e-05 | 199 | 66 | 6 | 4255_UP | |
| Drug | NSC56408 | 3.17e-05 | 62 | 66 | 4 | CID000005604 | |
| Drug | kt S | 4.05e-05 | 66 | 66 | 4 | CID006399216 | |
| Drug | azelastine | 6.36e-05 | 74 | 66 | 4 | CID000002267 | |
| Drug | p11-13 | 6.71e-05 | 75 | 66 | 4 | CID000015759 | |
| Drug | BW755C | 1.55e-04 | 93 | 66 | 4 | CID000047795 | |
| Drug | bipy | 1.82e-04 | 97 | 66 | 4 | CID000001474 | |
| Drug | 5224221; Down 200; 12uM; MCF7; HT_HG-U133A_EA | 2.06e-04 | 186 | 66 | 5 | 839_DN | |
| Drug | Felodipine [72509-76-3]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 2.11e-04 | 187 | 66 | 5 | 5294_UP | |
| Drug | Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 2.16e-04 | 188 | 66 | 5 | 6451_DN | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A | 2.33e-04 | 191 | 66 | 5 | 4279_DN | |
| Drug | Dexamethasone acetate [1177-87-3]; Up 200; 9.2uM; PC3; HT_HG-U133A | 2.44e-04 | 193 | 66 | 5 | 2079_UP | |
| Drug | Doxycycline hydrochloride [10592-13-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.44e-04 | 193 | 66 | 5 | 3479_DN | |
| Drug | Androsterone [53-41-8]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 2.50e-04 | 194 | 66 | 5 | 5696_DN | |
| Drug | Alsterpaullone; Up 200; 10uM; MCF7; HT_HG-U133A | 2.50e-04 | 194 | 66 | 5 | 7051_UP | |
| Drug | Tenoxicam [59804-37-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.50e-04 | 194 | 66 | 5 | 4182_UP | |
| Drug | Dirithromycin [62013-04-1]; Down 200; 4.8uM; MCF7; HT_HG-U133A | 2.50e-04 | 194 | 66 | 5 | 7446_DN | |
| Drug | Methylergometrine maleate [113-42-8]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 2.50e-04 | 194 | 66 | 5 | 5303_UP | |
| Drug | (R)-Propranolol hydrochloride [13071-11-9]; Down 200; 13.6uM; PC3; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 5814_DN | |
| Drug | pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 5977_DN | |
| Drug | Bambuterol hydrochloride [81732-46-9]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 7239_DN | |
| Drug | Delcorine; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 3613_UP | |
| Drug | Doxylamine succinate [562-10-7]; Down 200; 10.2uM; PC3; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 4235_DN | |
| Drug | Tetrandrine [518-34-3]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 2.56e-04 | 195 | 66 | 5 | 6082_DN | |
| Drug | Vinpocetine [42971-09-5]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 7213_UP | |
| Drug | Quinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 6267_DN | |
| Drug | Mesoridazine besylate [32672-69-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 7017_DN | |
| Drug | Forskolin, from Coleus forskohlii; Down 200; 0.5uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 7055_DN | |
| Drug | estradiol, USP; Down 200; 0.01uM; ssMCF7; HG-U133A | 2.62e-04 | 196 | 66 | 5 | 373_DN | |
| Drug | Evoxine [522-11-2]; Down 200; 11.6uM; HL60; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 2186_DN | |
| Drug | Aceclofenac [89796-99-6]; Up 200; 11.2uM; PC3; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 7269_UP | |
| Drug | clozapine; Down 200; 10uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 6988_DN | |
| Drug | (d,l)-Tetrahydroberberine [522-97-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 2818_UP | |
| Drug | Sulfinpyrazone [57-96-5]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 2.62e-04 | 196 | 66 | 5 | 3192_DN | |
| Drug | Miconazole [22916-47-8]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 1477_DN | |
| Drug | nifedipine; Up 200; 10uM; MCF7; HG-U133A | 2.69e-04 | 197 | 66 | 5 | 335_UP | |
| Drug | Benzethonium chloride [121-54-0]; Down 200; 9uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 7207_DN | |
| Drug | Phenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 6100_DN | |
| Drug | Roxithromycin [80214-83-1]; Up 200; 4.8uM; HL60; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 2992_UP | |
| Drug | Progesterone [57-83-0]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 4992_UP | |
| Drug | LY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 1641_DN | |
| Drug | Meticrane [1084-65-7]; Down 200; 14.6uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 1671_DN | |
| Drug | Levopropoxyphene napsylate [5714-90-9]; Up 200; 7.4uM; PC3; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 5083_UP | |
| Drug | 3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 4764_DN | |
| Drug | Piribedil hydrochloride [78213-63-5]; Up 200; 12uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 3512_UP | |
| Drug | Nimesulide [51803-78-2]; Down 200; 13uM; MCF7; HT_HG-U133A | 2.69e-04 | 197 | 66 | 5 | 2275_DN | |
| Drug | S(-)-terguride hydrogen maleate [37686-85-4]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 6473_DN | |
| Drug | Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; PC3; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 6696_DN | |
| Drug | benserazide hydrochloride; Up 200; 10uM; SKMEL5; HG-U133A | 2.75e-04 | 198 | 66 | 5 | 631_UP | |
| Drug | Metanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; MCF7; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 5334_DN | |
| Drug | 0225151-0000 [351320-15-5]; Up 200; 10uM; PC3; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 6426_UP | |
| Drug | celecoxib; Up 200; 10uM; PC3; HG-U133A | 2.75e-04 | 198 | 66 | 5 | 482_UP | |
| Drug | Nitrendipine [39562-70-4]; Down 200; 11uM; MCF7; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 5405_DN | |
| Drug | Naloxone hydrochloride [357-08-4]; Down 200; 11uM; MCF7; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 5243_DN | |
| Drug | Atropine-N-oxide hydrochloride [4574-60-1]; Down 200; 11.8uM; PC3; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 2054_DN | |
| Drug | Isoniazid [54-85-3]; Up 200; 29.2uM; PC3; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 2083_UP | |
| Drug | Estradiol-17 beta [50-28-2]; Down 200; 14.6uM; HL60; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 1299_DN | |
| Drug | Metolazone [17560-51-9]; Up 200; 11uM; HL60; HG-U133A | 2.75e-04 | 198 | 66 | 5 | 2014_UP | |
| Drug | Hydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; HL60; HG-U133A | 2.75e-04 | 198 | 66 | 5 | 1775_UP | |
| Drug | Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.75e-04 | 198 | 66 | 5 | 5645_DN | |
| Drug | Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 2329_UP | |
| Drug | Galanthamine hydrobromide [1953-04-4]; Up 200; 10.8uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 2787_UP | |
| Drug | Gibberellic acid [77-06-5]; Up 200; 11.6uM; PC3; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 4234_UP | |
| Drug | Vidarabine [5536-17-4]; Down 200; 15uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 7203_DN | |
| Drug | Piroxicam [36322-90-4]; Down 200; 12uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 2252_DN | |
| Drug | Levamisole hydrochloride [16595-80-5]; Down 200; 16.6uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 2257_DN | |
| Drug | Nicergoline; Down 200; 8.2uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 2220_DN | |
| Drug | Cytisine (-) [485-35-8]; Up 200; 21uM; MCF7; HT_HG-U133A | 2.81e-04 | 199 | 66 | 5 | 6217_UP | |
| Drug | Flurbiprofen [5104-49-4]; Up 200; 16.4uM; MCF7; HT_HG-U133A | 2.88e-04 | 200 | 66 | 5 | 5634_UP | |
| Drug | Sulfabenzamide [127-71-9]; Up 200; 14.4uM; MCF7; HT_HG-U133A | 2.88e-04 | 200 | 66 | 5 | 2814_UP | |
| Drug | carbonyl sulfide | 3.61e-04 | 116 | 66 | 4 | CID000010039 | |
| Drug | TXB2 (thromboxane B2 | 3.86e-04 | 118 | 66 | 4 | CID000005461 | |
| Disease | Male sterility due to Y-chromosome deletions | 1.23e-09 | 8 | 62 | 4 | C2931163 | |
| Disease | Partial chromosome Y deletion | 1.23e-09 | 8 | 62 | 4 | C1507149 | |
| Disease | Spermatogenic Failure, Nonobstructive, Y-Linked | 4.85e-06 | 16 | 62 | 3 | C1839071 | |
| Disease | SPERMATOGENIC FAILURE, Y-LINKED, 2 | 4.85e-06 | 16 | 62 | 3 | 415000 | |
| Disease | Spermatogenic failure, Y-linked, 2 | 4.85e-06 | 16 | 62 | 3 | cv:C1839071 | |
| Disease | tumor necrosis factor-alpha measurement | 1.52e-04 | 49 | 62 | 3 | EFO_0004684 | |
| Disease | Nephrotic Syndrome | 1.47e-03 | 27 | 62 | 2 | C0027726 | |
| Disease | cortical surface area measurement | 1.90e-03 | 1345 | 62 | 9 | EFO_0010736 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| HHSKNERPARPPPPI | 256 | Q8IVM0 | |
| GQPRPPHRPAQACRK | 61 | Q9NTK1 | |
| HKPAPRKEPRPNIPL | 676 | P51816 | |
| RPPPPGHRVQHQPQK | 296 | P06729 | |
| HQQKGPPLPRPRVQP | 321 | P06729 | |
| RNHRAPPLTPSKPPV | 436 | O95267 | |
| RPPVPPKRQENPGHP | 626 | Q7Z5R6 | |
| LLKDRHPPAPSPQNP | 66 | P78524 | |
| ARHVQPRPLVVNPPP | 121 | Q13117 | |
| ARHVQPRPLVVNPPP | 121 | Q9NR90 | |
| PRPPIHQQPPERRVV | 11 | Q14728 | |
| NRPNPLLALPPARPH | 256 | Q96AD5 | |
| PRPEKPRHPPLAKEN | 1551 | Q7RTP6 | |
| PRHPPLAKENGRLPA | 1556 | Q7RTP6 | |
| KQRGDIHPRPPPPRD | 641 | P10071 | |
| RIVPPLQHNSPPPKE | 136 | Q3KP22 | |
| HKQPPPREPARAQAP | 786 | O75420 | |
| PPRRPPPHILDQVKS | 841 | Q8N201 | |
| RPRQAPVPPASHAPA | 1781 | Q9P219 | |
| LRIQPTKPPNHRPAE | 4926 | Q9Y6V0 | |
| ANRNHPALPLSPPLP | 281 | Q96HM7 | |
| PARPASAPQRHPAPV | 36 | A0PJZ3 | |
| ENRQLPPPSPQLPKH | 136 | Q14678 | |
| TDFPKVVNRPRPHPP | 76 | Q8N4P6 | |
| RGNIHPPRDPNPPQL | 226 | Q96RP7 | |
| PPPKPAHRNSNPVIA | 261 | Q8IZ21 | |
| LRDIPLRPHPPDPQA | 626 | Q3KR16 | |
| LRPHPPDPQAPQRRS | 631 | Q3KR16 | |
| RAPPSHRPLKSPQNE | 281 | Q9UKJ1 | |
| ARHVQPRPLVVNPPP | 121 | Q9NQZ3 | |
| ARHVQPRPLVVNPPP | 286 | Q9NQZ3 | |
| ARHVQPRPLVVNPPP | 451 | Q9NQZ3 | |
| QDPPHVPPRVPRAAR | 271 | P58505 | |
| RSPKPPQAPQHPEEH | 801 | Q2TAC2 | |
| LQPEGDPPSRPRKPH | 46 | A0A1B0GUA9 | |
| TVPVPPLEPARPNRH | 56 | Q9H293 | |
| ARHVQPRPLVVNPPP | 121 | Q86SG3 | |
| ARHVQPRPLVVNPPP | 286 | Q86SG3 | |
| LRPVRAAPPPPTQNH | 711 | O94868 | |
| AAPPPPTQNHRRPAE | 716 | O94868 | |
| ERRQKPVVHPSAPAP | 36 | Q96DZ5 | |
| PPQPVNPPRPFKHSE | 396 | A8MW92 | |
| PRPQRPAETKAHLPP | 346 | A1L443 | |
| PAETKAHLPPPRPQR | 351 | A1L443 | |
| AHLPPPRPQRPAETN | 356 | A1L443 | |
| PRPQRPAETNAHLPP | 361 | A1L443 | |
| PAETNAHLPPPRPQR | 366 | A1L443 | |
| AHLPPPRPQRPAETK | 371 | A1L443 | |
| PRPQRPAETKAHLPP | 346 | Q5VZR2 | |
| PPVPAEHRAPPQIRR | 101 | Q9BW62 | |
| APEQPAPEPKHPARA | 186 | Q9Y2J0 | |
| RRARAKPQAEPPPPA | 46 | Q6ZMZ0 | |
| PVPPRQNSSPHLPKL | 1291 | Q07890 | |
| SRPPPVVVPHQPRLD | 491 | Q9BU23 | |
| QHLVPSPPKHPRPRD | 446 | Q8IYG6 | |
| QHAQPPPQPRKKRPE | 66 | O15530 | |
| NHPPIPRAVKPEPTN | 341 | Q9UPW6 | |
| SVNPNEIKPHPPTPR | 1756 | Q9HCD6 | |
| KEPARAPPEPPHNLF | 161 | Q9UJW9 | |
| DHDNPPPPQQTPLRK | 46 | P55201 | |
| QPRHSREVPRPPVPQ | 96 | Q8N7H1 | |
| EQTPLPQKRLPTPHP | 711 | Q9H3T3 | |
| AHKEKPNQPAPRPPR | 31 | Q9BZV1 | |
| FPQPAPRQPHLASRP | 226 | Q96BF3 | |
| VPPHRSIPPADPRKN | 306 | P51512 | |
| PQPNKRHSPSPRPRA | 676 | Q8IYB3 | |
| PRAHPHQPEDRVPPN | 2391 | Q5T1R4 | |
| QHQPDRRRQPVSPPP | 1286 | Q9Y6N7 | |
| RPDLKPPPHAQQAPL | 221 | O15090 | |
| LPAHPSNPQLPEARP | 1351 | O43379 | |
| EKPRVQEKQHPVPPP | 321 | Q15942 | |
| PPRLPQAGARDPPVH | 816 | Q5SXM2 | |
| PRDRPPPPHNTPKRN | 296 | A2RU30 | |
| PEPERSPPNRKRPAN | 256 | Q9NZ63 | |
| VPPAPQPPRRSRDHN | 606 | Q6ZMP0 | |
| HAAPKPPQLRSPRLP | 606 | Q9UEG4 | |
| PTHPRRKPLPPNNVT | 706 | Q7Z7G0 | |
| VPKPPPNHEQVLRRA | 1226 | Q6EMB2 | |
| RPQSRDPFAPLHKPP | 2456 | O14686 |